Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. on July 14, 2011. The filing addresses corporate governance changes, specifically the departure of a director and the appointment of a new Chairman of the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation and board composition.
Material Changes
- Board Resignation: John Pappajohn resigned from the Board of Directors effective July 14, 2011.
- Chairman Appointment: Mitchel Sayare, Ph.D., was named Chairman of the Board effective July 15, 2011. Dr. Sayare had previously served as a Board member since April 2010.
- Compensation Arrangements:
- Dr. Sayare received an option to purchase 60,000 shares of common stock. Vesting is structured as one-third immediately, one-third on the second anniversary, and one-third on the third anniversary.
- Dr. Sayare received an additional option to purchase 52,139 shares in lieu of 50% of his cash retainer for the Chairman and Governance Committee roles over the next three years. These options vest in equal quarterly installments starting October 15, 2011.
- The exercise price for all options is $2.67 per share, based on the closing price on July 15, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding and the dilution impact of the 112,139 new options granted to Dr. Sayare.
- Confirm the terms of the 2007 Long-Term Incentive Compensation Plan under which these options were granted.
- Review the Company's recent stock price performance relative to the $2.67 exercise price.
- Check for any subsequent filings regarding the resignation of John Pappajohn or further board changes.